Please login to the form below
EPO
This page shows the latest EPO news and features for those working in and with pharma, biotech and healthcare.
UK Supreme Court rules in favour of Servier in NHS patent lawsuit
The patent was then revoked in 2009. The NHS initially sued Servier in 2001, accusing Servier of deceiving the European Patent Office (EPO) in order to uphold the patent, causing financial
Latest news
-
Astellas files new application for expanded use of roxadustat in Japan
It is thought that mechanism causes lower but more consistent EPO levels in the blood.
-
GSK files anaemia drug daprodustat in Japan, its first market
In contrast, HIF-PHI drugs stimulate endogenous production of erythropoietin, and their developers think this mechanism leads to lower but more consistent EPO levels in the blood, thus avoiding complications.
-
China first market to approve AZ’s kidney drug roxadustat
It is though that mechanism causes lower but more consistent EPO levels in the blood.
-
Geron poleaxed as partner J&J abandons only pipeline drug
In the study imetelstat is being given to patients with anaemia who haven’t responded to a blood cell-boosting agent like EPO in the hope of removing their reliance on
-
‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’
As the European Patent Organisation (“EPO”) is independent of the EU, protection for European patents granted in the UK will continue to be available through the EPO post-Brexit, even in
More from news
Approximately 1 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
After the introduction of biosimilars in Portugal for erythropoietin (EPO), a hormone produced by the kidneys to stimulate production and maintenance of crucial red blood cells, the originator product was reduced
-
2016: The year when deal-makers took stock?
product. (According to the journal Biosimilar Development the price of EPO in Norway was sold at an 83% discount from the original price.).
-
Can biosimilars live up to the hype?
For instance, in Germany, an estimated 0.5bn has been saved with the introduction of Epo biosimilars and there has been a dramatic expansion in the use of the biosimilar filgrastim
-
Deal Watch February 2016
licence. 105. †† Genexine/ Shanghai Chemo WanBang Biopharma. GX-E2 (EPO-hyFc), a novel Fc-engineered (hyFc) long acting EPO, for anaemia due to chronic kidney disease and chemotherapy.
-
An eye towards the biobetter in South Korea
EPO-Fc. EPO-hybrid Fc. Anaemia. S Korea. Phase I. Hanferon (HL143). HanAll Biopharma. ... Hormone deficiency. S Korea. Phase I Completed Dec 2011. HL033. Improved EPO.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
